Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

Babatin, Mohamed; Alghamdi, Abdullah S; Assiri, Abdullah M.; Albiladi, Haziz; Alothmani, Hammad S.; Mogharbel, Mohammed; Mahallawi, Wedad; Asselah, Tarik; Sanai, Faisal M.

doi:10.4103/sjg.sjg_189_18

Cited by 5 publications

(3 citation statements)

References 19 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The addition of ribavirin has not been found to improve the efficacy of the combination regimen[158,159]. In a recent real-world study, an 8-wk regimen of ledipasvir + sofosbuvir was found to be well-tolerated and effective in treatment-naïve and noncirrhotic HCV GT4-infected patients ( n = 45) (SVR12: 97.8%)[160]. Studies evaluating the efficacy of sofosbuvir + ledipasvir + ribavirin regimen in HCV GT4-infected liver transplant recipients are limited.…”

Section: Optimizing the Management Of Hcv Infectionmentioning

confidence: 99%

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Colombo

Musabaev²,

Ismailov³

et al. 2019

WJG

View full text Add to dashboard Cite

Globally, 69.6 million individuals were infected with hepatitis C virus (HCV) infection in 2016. Of the six major HCV genotypes (GT), the most predominant one is GT1, worldwide. The prevalence of HCV in Central Asia, which includes most of the Commonwealth of Independent States (CIS), has been estimated to be 5.8% of the total global burden. The predominant genotype in the CIS and Ukraine regions has been reported to be GT1, followed by GT3. Inadequate HCV epidemiological data, multiple socio-economic barriers, and the lack of region-specific guidelines have impeded the optimal management of HCV infection in this region. In this regard, a panel of regional experts in the field of hepatology convened to discuss and provide recommendations on the diagnosis, treatment, and pre-, on-, and posttreatment assessment of chronic HCV infection and to ensure the optimal use of cost-effective antiviral regimens in the region. A comprehensive evaluation of the literature along with expert recommendations for the management of GT1-GT6 HCV infection with the antiviral agents available in the region has been provided in this review. This consensus document will help guide clinical decision-making during the management of HCV infection, further optimizing treatment outcomes in these regions.

show abstract

Section: Optimizing the Management Of Hcv Infectionmentioning

confidence: 99%

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Colombo

Musabaev²,

Ismailov³

et al. 2019

WJG

View full text Add to dashboard Cite

show abstract

“…A recent study of 8 weeks of therapy with LDV/SOF found that SVR12 was achieved in 97% of treatment-naïve HCV GT1 patients overall, but the SVR12 rates were lower (93%) in patients with stage 3 ibrosis and in African Americans (83%), warranting some consideration in these speci ic patient populations [5]. Of note, there is also emerging evidence of SVR rates ≥ 95% with the use of 8 weeks of LDV/SOF therapy in GT4 in noncirrhotic treatment-naïve patients; however, this is an offlabel use [6,7].…”

Section: More Informationmentioning

confidence: 99%

Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection

Lemoine¹,

Segarra‐Newnham²

2019

Ann Clin Gastroenterol Hepatol

View full text Add to dashboard Cite

Hepatitis C Virus (HCV) infection is usually treated with direct acting antivirals (DAAs) for 12 weeks. In treatment naive patients with genotype (GT) 1 infection without cirrhosis and baseline viral load <6 million, 8 weeks of Ledipasvir/Sofosbuvir (LDV/SOF) is an option. Eight weeks with Glecaprevir/Pibrentasvir (GLE/PIB) is an option for patients with GT 1 through 6 without cirrhosis. Our objective was to evaluate achievement of Sustained Virologic Response (SVR) after 8 weeks of LDV/SOF or GLE/PIB in our HCV-infected veterans. Patients with HCV infection that received GLE/ PIB or LDV/SOF for a planned 8 weeks of therapy in the past four years were reviewed (January 2015-September 2018). Treatment outcomes were evaluated through medical record review. Two hundred sixty-fi ve veterans were initiated on 8 weeks of therapy with either GLE/PIB or LDV/SOF. Of these, 231 (87%) were initiated on 8 weeks of LDV/SOF and 34 (13%) were initiated on 8 weeks of GLE/PIB. The majority of patients had GT 1 (93%) infection. One hundred and ninetyfi ve veterans who completed 8 weeks of LDV/SOF and 30 veterans on GLE/PIB had follow-up viral loads. The overall SVR was 95%. Treatment with GLE/PIB resulted in a higher SVR rate (100%) compared to LDV/SOF (95%). Elderly patients had similar SVR rates. Treatment with 8 weeks of DAA is effective in our veteran population and showed an SVR rate similar to literature reports. The SVR for patients treated with 8 weeks LDV/SOF was slightly lower than the SVR for GLE/PIB; however, the GLE/PIB population was smaller.

show abstract

“…Treatment regimens are now of shorter duration, less difficult to tolerate, and more effective. [ 8 ] The introduction of these new treatment options can result in greater reduction of prevalence rates. [ 9 ]…”

Section: Introductionmentioning

confidence: 99%

Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia

Alotaibi

Shamas

Ansari

et al. 2021

Journal of Pharmacy and Bioallied Sciences

Self Cite

View full text Add to dashboard Cite

Background: Ministry of National Guard–Health Affairs in Saudi Arabia developed a new policy for the use of direct antiviral agents (DAAs) for hepatitis C. The present study was conducted to evaluate prescribers' compliance and the impact of the policy on DAAs appropriate use. Materials and Methods: This study was conducted at King Abdul Aziz Medical City in Jeddah, Saudi Arabia. The study compares patients' data during 1 year before and 1 year after policy initiation. The primary outcomes were compliance to monitoring parameters, appropriateness of treatment and treatment eligibility. Secondary outcomes included sustained virologic response at 12 weeks, documentation of potential drug–drug interactions and treatment costs. Independent samples t -test and Chi-square test were used when applicable. A P < 0.05 was considered statistically significant. Results: One hundred and three patients were included in analysis (46 before and 57 after policy). Prescriber compliance to baseline monitoring parameters was 67.4% before policy and 82.5% after-policy ( P = 0.076). International normalized ratio (INR) was requested in 84.8% of cases before policy compared to 96.5% after-policy ( P = 0.036). Treatment options offered to patients were appropriate in 52.2% of cases before policy and in 82.5% after-policy ( P = 0.001). Conclusion: There is a significant improvement in the baseline monitoring of INR. Treatment options offered after policy implementation were significantly more appropriate.

show abstract

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

Abstract: An 8-week regimen of LDV/SOF was well tolerated and efficacious in this treatment-naïve, non-cirrhotic HCV GT4-infected population. This study provides valuable information on a short treatment regimen for HCV GT4 infection in a real-world setting.

Cited by 5 publications

References 19 publications

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection

Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia

Contact Info

Product

Resources

About